Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Despite the potent suppression of the hepatitis B virus with modern antiviral agents, only a minority of HBeAg-positive patients achieve hepatitis B e antigen seroconversion. We aimed to explore the potential efficacy of combination therapy consisting of pegylated interferon (p-IFN) and an oral antiviral agent in patients with HBeAgpositive chronic hepatitis B. Methods: The treatment protocol consisted of p-IFN-a-2a at 180 μg/wk for 48 weeks, with either entecavir or tenofovir added 8 weeks after the initiation of p-IFN and continued for at least 6 months after HBe seroconversion was achieved. Results: To date, 10 patients have been treated under the protocol (eight adults, mean age 36±8 years; two adolescents, aged 12 and 16 years). All eight adult patients experienced loss of HBeAg at a mean of 72.3±66.9 weeks, including six patients who also developed anti-HBe and one patient who had HBs seroconversion. Although both adolescents remain on therapy, one adolescent had HBs seroconversion without HBe seroconversion. A total of nine of our 10 patients experienced a favorable serological transition. Conclusions: The combination of p-IFN and a modern oral antiviral agent may be more effective than monotherapy with either class of agent in the treatment of HBeAg-positive chronic hepatitis B patients.
Abstract
Background/Aims: Despite the potent suppression of the hepatitis B virus with modern antiviral agents, only a minority of HBeAg-positive patients achieve hepatitis B e antigen seroconversion. We aimed to explore the potential efficacy of combination therapy consisting of pegylated interferon (p-IFN) and an oral antiviral agent in patients with HBeAgpositive chronic hepatitis B. Methods: The treatment protocol consisted of p-IFN-a-2a at 180 μg/wk for 48 weeks, with either entecavir or tenofovir added 8 weeks after the initiation of p-IFN and continued for at least 6 months after HBe seroconversion was achieved. Results: To date, 10 patients have been treated under the protocol (eight adults, mean age 36±8 years; two adolescents, aged 12 and 16 years). All eight adult patients experienced loss of HBeAg at a mean of 72.3±66.9 weeks, including six patients who also developed anti-HBe and one patient who had HBs seroconversion. Although both adolescents remain on therapy, one adolescent had HBs seroconversion without HBe seroconversion. A total of nine of our 10 patients experienced a favorable serological transition. Conclusions: The combination of p-IFN and a modern oral antiviral agent may be more effective than monotherapy with either class of agent in the treatment of HBeAg-positive chronic hepatitis B patients.
참고문헌 (27)
- Shepard CW, "Hepatitis B virus infection: epidemiology and vaccination", Epidemiol Rev, 28, pp.112~125 (2006)
- Chang TT, "Long-term entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
- Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
- Buster EH, "Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b", Gastroenterology, 135, pp.459~467 (2008)
- van Zonneveld M, "Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B", Hepatology, 39, pp.804~810 (2004)
- Chan HL, "A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone", Ann Intern Med, 142, pp.240~250 (2005)
- Lau GK, "Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B", N Engl J Med, 352, pp.2682~2695 (2005)
- Janssen HL, "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial", Lancet, 365, pp.123~129 (2005)
- Terrault NA, "Benefits and risks of combination therapy for hepatitis B", Hepatology, 49, pp.S122~S128 (2009)
- Bedossa P, "An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group", Hepatology, 24, pp.289~293 (1996)
- The French METAVIR Cooperative Study Group, "Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C", Hepatology, 20, pp.15~20 (1994)
- Perrillo R, "Benefits and risks of interferon therapy for hepatitis B", Hepatology, 49, pp.S103~S111 (2009)
- European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Woo G, "Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses", Gastroenterology, 139, pp.1218~1229 (2010)
- Hagiwara S, "Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B", J Med Virol, 85, pp.987~995 (2013)
- Boglione L, "Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes", J Viral Hepat, 20, pp.e11~e19 (2013)
- Enomoto M, "Entecavir and interferon-alfa sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B", J Gastroenterol, 48, pp.397~404 (2013)
- Ryu SH, "Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study", J Hepatol, 39, pp.614~619 (2003)
- Yuen MF, "Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications", Hepatology, 34, pp.139~145 (2001)
- Dienstag JL, "Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy", Hepatology, 30, pp.1082~1087 (1999)
- Dienstag JL, "Durability of serologic response after lamivudine treatment of chronic hepatitis B", Hepatology, 37, pp.748~755 (2003)
- Lau DT, "Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa", Gastroenterology, 113, pp.1660~1667 (1997)
- Shah U, "Management of chronic hepatitis B in children", J Pediatr Gastroenterol Nutr, 48, pp.399~404 (2009)
- Liaw YF, "Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C", Hepatology, 54, pp.1591~1599 (2011)
- Chan HL, "Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B", Antivir Ther, 12, pp.815~823 (2007)